SHENZHEN Hemogen Therapeutic Co., Ltd.

January 2022: Completed the first round of 20 million financing

February 2022: First patient achieved blood transfusion independence for one year

February 2021: Completed engineered cell reinfusion of the first patient

July 2021: HGI was officially registered and established

July 2021: Assisted the partner hospital to complete the first case of "CD34+-SCB" in Shenzhen for the treatment of graft dysfunction

September 2021: HGI won second prize in the Yantian sub-venue of the "Science and Technology China" Innovation and Venture Capital Conference (2021)

July 2020: Completed the construction of GMP standard facility

September 2020: Completed gene therapy preparation for the first patient

November 2020: Pre-clinical study results accepted for publication in Human Gene Therapy

June 2019: Established the genetic engineering platform 

November 2019: Completed the preparation of lentiviral vector